ClinicalTrials.gg
CompletedNCT04977167Updated Sep 21, 2026

Clinical Trial of HG146 Administered to Subjects With Advanced Solid Tumors or Lymphoma

A Phase 1 interventional study of HG146 and PD-(L)1 antibody in Solid Tumor and Lymphoma, sponsored by HitGen Inc.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by HitGen Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 276 studies in Lymphoma with a site in China — 103 open to participants now, 119 under way, 10 of them phase 3. Lymphoma · China.

Enrollment
167th of 232
24 · median 47
Started
2021
with 25 others
Phase 1
83 of 276
25 open now
Registered
138th of 276
by date

Among the 276 studies in Lymphoma with a site in China, this one is the 167th largest by enrollment of the 232 interventional ones that give a count, is one of 26 that started in 2021, is one of 83 in phase 1, and was the 138th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 435 are open to participants now.

Browse Lymphoma studies →

Open to participants now

103 of the 276 studies in Lymphoma with a site in China are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 347 Lymphoma studies recruiting now, 228 (66%) set no upper age limit and 78 (22%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Lymphoma with a site in China, or all of them as a file.
02

Study summary

This is a Phase I, open-label, repeat-dose, non-randomized, multicenter study to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of HG146 administered orally (PO) alone (Part 1) or co-administered (Part 2) with PD-(L)1 inhibitor in subjects with refractory/relapsed solid tumors or Lymphoma. Part 1 consists of a dose escalation phae,Part2 consists of a dose escalation phase and a cohort expansion phase. In Part 1, escalating doses of HG146 will be evaluated as guided by the "3+3" approach. In Part 2A, escalating doses of HG146 in combination with PD-(L)1 inhibitor will be evaluated as guided by the "3+3" approach. In Part 2B, subjects will receive a single dose level of HG146 as identified based on data from Part 2, in combination with PD-(L)1 inhibitor . A total of approximately 96 subjects will be enrolled in this study, approximately 36 for dose escalation cohorts, and approximately 60 in the expansion cohorts.

03

Conditions studied

  • Solid Tumor
  • Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

1 Subject must be >=18 years of age at the time of signing the .

2- Ia/Ib dose escalation phase(Part1 and Part 2A):Subjects with advanced/ solid tumors or Lymphoma, who have progressed on, be intolerant of, or ineligible for, all available therapies for which clinical benefit has been established.

  • Ib dose expansion phase(Part 2):

    1. Cohort 1,Subjects with advanced/Metastatic solid tumors or Lymphoma, who have progressed on, be intolerant of, or ineligible for, all available therapies for which clinical benefit has been established, have not been treated with PD-(L)1 antibody; 2)Cohort 2,Subjects with advanced/Metastatic solid tumors or Lymphoma, who have progressed on, be intolerant of, or ineligible for, all available therapies for which clinical benefit has been established, have progressed on PD-(L)1 antibody; 3 per version 1.1 or Lugano 2014(If applicable). 4 Has (ECOG) Performance Status ≤1. 5 Has adequate organ function. 6 Signed informed consent form (ICF) and able to comply with study requirements.

Key Exclusion Criteria:

  1. Received prior therapies targeting HDAC.
  2. Symptomatic central nervous system (CNS) metastases that have required within 4 weeks prior to first dose of study treatment.
  3. History of intolerant of anti-PD-(L)1 toxicity(Ib).
  4. A condition requiring systemic treatment with either corticosteroids or other medications within 14 days of enrollment.
  5. Major surgery or major injury \<=28 days before the first dose of study treatment,or anticipated major surgery during the study.
  6. Received other anticaner therapies within 4 weeks prior to first dose of study treatment or 5 half life period of anticancer drug .
  7. Active infection requiring systemic treatment.
  8. Prior bone marrow transplantation or other solid organ transplantation ( Ib)
  9. Active disease or disease of impaired immune system(Ib).
  10. History of Adrenal insufficiency.(Ib)
  11. History orConcurrent condition of other malignant tumors.
  12. Recent (within the past 6 months) history of Unstable or serious diseases, such as pancreatitis, severe angina, prolonged , congestive heart failure, myocardial infarction, pulmonary hypertension, stroke, and severe seizures, etc.
  13. History of severe lung disease.
  14. Any illness or medical conditions that are unstable or could jeopardize the safety of the patient and his/her compliance in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Part 1:HG146 Monotherapy, Dose-escalation Cohort

    Subjects will receive HG146 PO at every two days intervals (qod) for 14 consecutive days,7 days off, 21 days/ cycle. Escalating doses of HG146 will be evaluated using 3+3 approach.

    Drug: HG146

  • Experimental
    Part 2A:HG146 + PD-(L)1 antibody, Dose escalation Cohort

    Subjects will receive HG146 PO at every two days intervals (qod) for 14 consecutive days,7 days off, along with PD-(L)1 antibody IV once every 3 weeks (Q3W),21 days/ cycle. Escalating doses of HG146 in combination with PD-(L)1 antibody will be evaluated.

    Drug: HG146 · Drug: PD-(L)1 antibody

  • Experimental
    Part 2B-1:HG146 combination Expansion Cohort 1

    Subjects who have not been treated with PD-(L)1 antibody,will receive HG146 po for 14 consecutive days,7 days off, in combination with PD-(L)1 antibody IV Q3W.

    Drug: HG146 · Drug: PD-(L)1 antibody

  • Experimental
    Part 2B-2:HG146 combination Expansion Cohort 2

    Subjects who have progressed on PD-(L)1 antibody, will receive HG146 po for 14 consecutive days,7 days off, in combination with PD-(L)1 antibody IV Q3W.

    Drug: HG146 · Drug: PD-(L)1 antibody

Interventions

  • DrugHG146

    HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.

    Also known as: HG146 capsule

  • PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.

    Also known as: PD-1 antibody

06

What researchers measure

Primary outcomes

  1. Part I:Dose-Limiting Toxicities (DLTs)

    Number of participants experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE V5.0)

    Time frame: Up to 26 Days in Cycle 0 and Cycle 1

  2. Part I:Serious Adverse Events (SAEs) and Adverse Events (AE)

    Number of participants experiencing Serious Adverse Events (SAEs) and Adverse Events (AE) According to Safety performance.

    Time frame: Up to 2 years

  3. Part I:Maximum tolerated dose or Recommended Phase Ib dose (RP2D) of HG146

    Maximum tolerated dose or Recommended Phase II dose of HG146 will be decided according to safety and effective results.

    Time frame: Up to 2 years

  4. Part 2A: Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v.5.0)

    Number of participants experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE V5.0)

    Time frame: Up to 21 Days in Cycle 1

  5. Part 2A: Serious Adverse Events (SAEs) and Adverse Events (AE)

    Number of participants experiencing Serious Adverse Events (SAEs) and Adverse Events (AE) According to Safety performance.

    Time frame: Up to 2 years

  6. Part 2A:Maximum tolerated dose or Recommended Phase II dose (RP2D) of HG146 in combination with PD-(L)1 antibody

    Maximum tolerated dose or Recommended Phase II dose of HG146 will be decided according to safety and effective results.

    Time frame: Up to 2 years

Secondary outcomes

  1. Part 1:Area under the concentration versus time curve (AUC) of HG146

    Plasma concentration of HG146 will be measured following single dose and multiple dose administration

    Time frame: At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15 (Except for cycle 0, each cycle is 21 days)

  2. Part 1:Peak plasma concentration (Cmax) of HG146

    Plasma concentration of HG146 will be measured following single dose and multiple dose administration

    Time frame: At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15 (Except for cycle 0, each cycle is 21 days)

  3. Part 1:Time of Cmax (Tmax) of HG146

    Plasma concentration of HG146 will be measured following single dose and multiple dose administration

    Time frame: At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15(Except for cycle 0, each cycle is 21 days)

  4. Part 1:Apparent terminal half-life (T1/2) of HG146

    Plasma concentration of HG146 will be measured following single dose and multiple dose administration

    Time frame: At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15 (Except for cycle 0, each cycle is 21 days)

  5. Part1: objective response rate (ORR)

    ORR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

    Time frame: Up to 2 years

  6. Part1: Best overall response (BOR)

    BOR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

    Time frame: Up to 2 years

  7. Part1: Duration of response (DOR)

    DOR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

    Time frame: Up to 2 years

  8. Part 1:Time-to-response (TTR)

    TTR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

    Time frame: Up to 2 years

  9. Part 1:Progression-Free Survival (PFS)

    PFS will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

    Time frame: Up to 2 years

  10. Part 2:Area under the concentration versus time curve (AUC) of HG146

    Plasma concentration of HG146 will be measured following multiple dose administration in combination with PD-(L)1 antibody

    Time frame: At the end of Cycle 1 Day 15 (each cycle is 21 days)

  11. Part 2:maximum observed plasma concentration (Cmax) of HG146

    Plasma concentration of HG146 will be measured following multiple dose administration in combination with PD-(L)1 antibody

    Time frame: At the end of Cycle 1 Day 15 (each cycle is 21 days)

  12. Part 2:time of maximum observed plasma concentration (Tmax) of HG146

    Plasma concentration of HG146 will be measured following multiple dose administration in combination with PD-(L)1 antibody

    Time frame: At the end of Cycle 1 Day 15 (each cycle is 21 days)

  13. Part 2:apparent terminal half-life (T1/2) of HG146

    Plasma concentration of HG146 will be measured following multiple dose administration in combination with PD-(L)1 antibody

    Time frame: At the end of Cycle 1 Day 15 (each cycle is 21 days)

  14. Part2: objective response rate (ORR)

    ORR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

    Time frame: Up to 2 years

  15. Part2: Best overall response (BOR)

    BOR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

    Time frame: Up to 2 years

  16. Part2: Duration of response (DOR)

    DOR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

    Time frame: Up to 2 years

  17. Part 2:Time-to-response (TTR)

    TTR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

    Time frame: Up to 2 years

  18. Part 2:Progression-Free Survival (PFS)

    PFS will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)

    Time frame: Up to 2 years

  19. Overall survival (OS)

    OS will be assessed by the investigators

    Time frame: Up to 2 years

07

Study locations

1 site
  • National Cancer Center/Cancer Hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Jun 2024, 32 months.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 32 months is below that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2021
First posted
Jul 26, 2021
StartActual
Sep 23, 2021
Primary completionActual
Jun 13, 2024
CompletionActual
Dec 22, 2024
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04977167
Lead sponsor
HitGen Inc.
Responsible party
Sponsor
First posted
Jul 26, 2021
Start date
Sep 23, 2021
Primary completion
Jun 13, 2024
Completion
Dec 22, 2024
Last update
Sep 21, 2026

Study contacts

Yuankai Shi
principal investigator · National Cancer Center/Cancer Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HDAC Class I/IIb Inhibitor HG146

Start the discussion